HTA4 Clinical Development and HTA Approval of MULTI-Indication Oncology Products: Evidence from Germany, France, England, Scotland, the US, Canada, and Australia

Abstract

Authors

M. Mills D. Michaeli A. Miracolo P. Kanavos

Full Text Cite This Article
Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×